Flavin-Conjugated Pt(IV) Anticancer Agents
Inorganic Chemistry · 10.04.2023 · 62 (14) · 5644-5651
DOI: 10.1021/acs.inorgchem.3c00193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inorganic Chemistry, online erschienen am 29.03.2023. Verfasst von Juan Sánchez-Camacho und 8 weiteren Autor:innen. Beteiligte Einrichtung: Donostia International Physics Center, Paseo Manuel de Lardizabal 4, Donostia 20018, Spain. Hauptthemen laut MEDLINE: Antineoplastic Agents, Prodrugs. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Comunidad de Madrid, Ministerio de Econom?a y Competitividad, Regione Calabria.
Abstract (Originalsprache)
In situ activation of Pt(IV) to Pt(II) species is a promising strategy to control the anticancer activity and overcome the off-target toxicity linked to classic platinum chemotherapeutic agents. Herein, we present the design and synthesis of two new asymmetric Pt(IV) derivatives of cisplatin and oxaliplatin (1·TARF and 2·TARF, respectively) bearing a covalently bonded 2',3',4',5'-tetraacetylriboflavin moiety (TARF). 1H and 195Pt NMR spectroscopy shows that 1·TARF and 2·TARF can be effectively activated into toxic Pt(II) species, when incubated with nicotinamide adenine dinucleotide, sodium ascorbate, and glutathione in the dark and under light irradiation. Density functional theory studies of the dark Pt(IV)-to-Pt(II) conversion of 2·TARF indicate that the process involves first hydride transfer from the donor to the flavin moiety of the complex, followed by electron transfer to the Pt(IV) center. When administered to MDA-MB-231 breast cancer cells preincubated with nontoxic amounts of ascorbate, 2·TARF displays enhanced toxicity (between 1 and 2 orders of magnitude), suggesting that the generation of oxaliplatin can selectively be triggered by redox activation. Such an effect is not observed when 2 and TARF are coadministered under the same conditions, demonstrating that covalent binding of the flavin to the Pt complex is pivotal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Donostia International Physics Center, Paseo Manuel de Lardizabal 4, Donostia 20018, Spain.
- IMDEA Nanociencia, Faraday 9, Madrid 28049, Spain.
- Department of Chemistry and Chemical Technologies, Università della Calabria, Arcavacata di Rende, Cosenza 87036, Italy.
- Centro de Física de Materiales, CSIC-UPV/EHU, Paseo Manuel Lardizábal 5, Donostia 20018, Spain.
- Ikerbasque, Basque Foundation for Science, Bilbao 48011, Spain.
- Unidad Asociada de Nanobiotecnología CNB-CSIC-IMDEA, Madrid 28049, Spain.
ORCID-Profile: Sonia Infante-Tadeo, Ana C Carrasco, Fabienne Barroso-Bujans, Emilia Sicilia, Ana M Pizarro, Luca Salassa
Förderung
- Comunidad de Madrid
- Ministerio de Econom?a y Competitividad
- Regione Calabria
- Eusko Jaurlaritza
- Diputaci?n Foral de Gipuzkoa
- Agencia Estatal de Investigaci?n,Ministerio de Ciencia, Innovaci?n y Universidades
Zitieren
APA
Sánchez-Camacho, J., Infante-Tadeo, S., Carrasco, A. C., Scoditti, S., Martínez, Á., Barroso-Bujans, F., Sicilia, E., Pizarro, A. M., & Salassa, L. (2023). Flavin-Conjugated Pt(IV) Anticancer Agents. Inorganic Chemistry, 62(14), 5644-5651. https://doi.org/10.1021/acs.inorgchem.3c00193
Vancouver
Sánchez-Camacho J, Infante-Tadeo S, Carrasco AC, Scoditti S, Martínez Á, Barroso-Bujans F, et al. Flavin-Conjugated Pt(IV) Anticancer Agents. Inorganic Chemistry. 2023;62(14):5644-5651. doi:10.1021/acs.inorgchem.3c00193
BibTeX
@article{SnchezCamacho2023,
author = {Sánchez-Camacho, Juan and Infante-Tadeo, Sonia and Carrasco, Ana C and Scoditti, Stefano and Martínez, Álvaro and Barroso-Bujans, Fabienne and Sicilia, Emilia and Pizarro, Ana M and Salassa, Luca},
title = {Flavin-Conjugated Pt(IV) Anticancer Agents},
journal = {Inorganic Chemistry},
year = {2023},
volume = {62},
number = {14},
pages = {5644--5651},
doi = {10.1021/acs.inorgchem.3c00193}
}
EUVIMED